Frontlight ResearchEarly access
Taking people in FinlandPhase 1
Stool transplant and drug-processing enzymes in irritable bowel syndrome or C. difficile
Tests stool transplant effects on drug-processing enzymes in gut conditions.
Key facts
- Who runs it
- HUS-Yhtymae
- Where
- Helsinki, FinlandSee the site
- Registry title
- KF2022#1 trial: The effect of fecal microbiota transplantation on CYP enzyme activities
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 25 people, planned
- Started
- 5 Jan 2023
- Planned end
- 31 Dec 2025
- Type of study
- Interventional
- Record updated
- 21 October 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with irritable bowel syndrome or Clostridioides difficile infection. It studies how a stool transplant from a donor (fecal microbiota transplantation) affects liver enzymes that break down drugs (CYP enzymes).
- Age
- 18 years and older
- Sex
- All sexes
Main reasons for not taking part
- Healthy volunteers cannot join.
Where in Finland
- HUS-YhtymaeHelsinki, FinlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- Stool transplant and drug-processing enzymes in irritable bowel syndrome or C. difficileGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 21 October 2024